Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention

Sponsor
University of Virginia (Other)
Overall Status
Completed
CT.gov ID
NCT02886143
Collaborator
(none)
274
2
9

Study Details

Study Description

Brief Summary

Urinary retention is a common problem, particularly in hospitalized patients. When a Foley catheter is removed, a patient must be monitored for urinary retention. The usual method is a passive voiding trial where the catheter is removed, the bladder fills with urine and the patient is monitored for voiding over approximately 6 hours. Another option is an active voiding trial where the bladder is filled with saline before the catheter is removed and the patient is immediately assisted to void. This study seeks to determine the effect of active vs passive voiding trials on time to hospital discharge, rate of urinary tract infections, and rate or urinary retention in the general hospitalized population.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Active Voiding Trial
  • Procedure: Passive Voiding Trial
Phase 3

Detailed Description

The intervention to be tested is an active voiding trial, where the bladder is filled with saline before the catheter is removed and the patient is immediately assisted to void.

Study Design

Study Type:
Interventional
Actual Enrollment :
274 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Active vs. Passive Voiding Trials on Time to Patient Discharge, Rate of Urinary Tract Infection, and Rate of Urinary Retention: a Randomized, Controlled Clinical Trial
Study Start Date :
Oct 1, 2015
Actual Primary Completion Date :
Jul 1, 2016
Actual Study Completion Date :
Jul 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Voiding Trial (instillation of sterile saline)

Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.

Procedure: Active Voiding Trial
Nursing protocol: Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push Clamp the Foley Deflate the catheter balloon and remove the catheter from the bladder. Record the amount of saline that was instilled into the bladder. Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate 7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter

Active Comparator: Passive Voiding Trial

For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.

Procedure: Passive Voiding Trial
Nursing protocol: Deflate the catheter balloon and remove the catheter from the bladder. Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours). 5. If the patient has not voided within 5 hours, assist the patient to try to void. 6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan. 7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter

Outcome Measures

Primary Outcome Measures

  1. time from removal of Foley catheter until hospital discharge [approximately one day]

    time from removal of the Foley catheter until the patient physically leaves the hospital

Secondary Outcome Measures

  1. urinary tract infection [within 2 weeks of hospital discharge]

    urinary tract infection within 2 weeks of hospital discharge based on the National Surgical Quality Improvement Program (NSQIP) definition (one of two of the following): One of the following: (fever (>38 C), urgency, frequency, dysuria, or suprapubic tenderness) AND urine culture of >10^5 colonies/mL urine with no more than 2 species of organisms Two of the following (fever (>38 C), urgency, frequency, dysuria, or suprapubic tenderness) AND any of the following: (dipstick test positive for leukocyte esterase and/or nitrite, pyuria (>10 white blood cells (WBC)/mL or >3 WBC/hpf of unspun urine), organisms seen on Gram stain of unspun urine, two urine cultures with repeated isolation of the same uropathogen with >10^2 colonies/mL urine in non-voided specimens, urine culture with <10^5 colonies/mL urine of single uropathogen in patient being treated with appropriate antimicrobial therapy, physician's diagnosis, physician institutes appropriate antimicrobial therapy)

  2. Urinary retention [within 2 weeks of hospital discharge]

    inability to urinate requiring urethral catheterization within 2 weeks of hospital discharge. This will be determined by asking the patient the number of times he or she has had a urethral catheter inserted in the 2 weeks since the catheter was removed

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admission to one of three hospital units at the University of Virginia (5 Central, 6 West, or the Short Stay Unit)

  • Patient has a Foley urethral catheter in place

  • The physician has ordered the Foley urethral catheter to be discontinued

  • 18 years of age and older

Exclusion Criteria:
  • Age less than 18 years

  • Prisoners

  • Women who are pregnant

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Virginia

Investigators

  • Principal Investigator: Tracey L Krupski, MD, MPH, University of Virginia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tracey Krupski, MD, Vice Chair, University of Virginia
ClinicalTrials.gov Identifier:
NCT02886143
Other Study ID Numbers:
  • 18345
First Posted:
Sep 1, 2016
Last Update Posted:
Sep 1, 2016
Last Verified:
Aug 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2016